SOPHiA GENETICS (NASDAQ:SOPH) Sees Unusually-High Trading Volume - Here's What Happened

SOPHiA GENETICS logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Trading volume rose 55% to about 549,217 shares; SOPHiA GENETICS last traded at $7.24, down from its prior close of $7.47.
  • Analyst views are mixed: three rate the stock Buy, one Hold and one Sell. The consensus rating is Hold, with a $10 average price target.
  • The latest quarter’s loss of $0.24 per share missed the $0.20 loss estimate, while revenue of $24.27 million slightly topped expectations of $24.03 million.
  • Five stocks we like better than SOPHiA GENETICS.

SOPHiA GENETICS SA (NASDAQ:SOPH - Get Free Report) shares saw unusually-strong trading volume on Thursday. Approximately 549,217 shares changed hands during trading, an increase of 55% from the average daily volume of 354,314 shares. The stock last traded at $7.24 and had previously closed at $7.47.

Analyst Ratings Changes

A number of analysts recently commented on SOPH shares. HC Wainwright reiterated a "buy" rating and issued a $14.00 price objective on shares of SOPHiA GENETICS in a research report on Monday, October 12th. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of SOPHiA GENETICS in a research note on Thursday, October 15th. Finally, BTIG Research increased their price target on SOPHiA GENETICS from $8.00 to $9.00 and gave the company a "buy" rating in a research note on Wednesday, August 5th. Three investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, SOPHiA GENETICS has an average rating of "Hold" and a consensus price target of $10.00.

Read Our Latest Stock Analysis on SOPH

SOPHiA GENETICS Trading Down 6.8%

The business's 50 day moving average price is $7.62 and its 200-day moving average price is $6.09. The company has a current ratio of 2.29, a quick ratio of 2.16 and a debt-to-equity ratio of 0.70. The company has a market cap of $583.83 million, a price-to-earnings ratio of -6.40 and a beta of 1.09.

SOPHiA GENETICS (NASDAQ:SOPH - Get Free Report) last issued its quarterly earnings results on Tuesday, November 3rd. The company reported ($0.24) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.20) by ($0.04). The company had revenue of $24.27 million during the quarter, compared to the consensus estimate of $24.03 million. SOPHiA GENETICS had a negative net margin of 89.18% and a negative return on equity of 128.69%. On average, equities analysts anticipate that SOPHiA GENETICS SA will post -0.94 EPS for the current fiscal year.

Insider Activity at SOPHiA GENETICS

In other news, insider Philippe Menu sold 7,394 shares of the firm's stock in a transaction that occurred on Monday, October 5th. The shares were sold at an average price of $8.13, for a total transaction of $60,113.22. Following the completion of the sale, the insider owned 200,993 shares in the company, valued at $1,634,073.09. This trade represents a 3.55% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Zhenyu Xu sold 10,000 shares of the stock in a transaction on Thursday, August 27th. The stock was sold at an average price of $8.91, for a total value of $89,100.00. Following the transaction, the insider owned 556,887 shares of the company's stock, valued at $4,961,863.17. The trade was a 1.76% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 148,162 shares of company stock valued at $1,199,254 over the last 90 days. Corporate insiders own 4.88% of the company's stock.

Institutional Investors Weigh In On SOPHiA GENETICS

Several large investors have recently bought and sold shares of SOPH. Goldman Sachs Group Inc. raised its holdings in SOPHiA GENETICS by 887.5% in the 3rd quarter. Goldman Sachs Group Inc. now owns 292,278 shares of the company's stock worth $2,449,000 after purchasing an additional 262,680 shares during the period. Jump Financial LLC bought a new stake in shares of SOPHiA GENETICS in the 3rd quarter worth about $1,875,000. AWM Investment Company Inc. raised its position in SOPHiA GENETICS by 3.8% during the third quarter. AWM Investment Company Inc. now owns 1,764,204 shares of the company's stock valued at $14,784,000 after purchasing an additional 64,204 shares during the period. Marshall Wace LLP bought a new stake in SOPHiA GENETICS in the third quarter worth $3,300,000. Finally, Steward Partners Investment Advisory LLC bought a new stake in shares of SOPHiA GENETICS in the 3rd quarter worth about $680,000. 31.59% of the stock is currently owned by institutional investors.

About SOPHiA GENETICS

(Get Free Report)

SOPHiA GENETICS is a healthcare technology company that develops data-analysis tools for genomics and other complex health data. Its cloud-based SOPHiA DDM platform uses artificial intelligence and analytics to help healthcare and research organizations interpret data and support clinical and scientific decision-making. The platform and related applications are used in areas including oncology, rare diseases and inherited conditions. The company serves hospitals, laboratories, biopharmaceutical companies and research organizations, with a presence across international markets.

Read More

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in SOPHiA GENETICS Right Now?

Before you consider SOPHiA GENETICS, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and SOPHiA GENETICS wasn't on the list.

While SOPHiA GENETICS currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

10 Stocks Powering The Next AI Boom  Cover

The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.

Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines